SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- Veteran financial executive Lawrence R. Moreau has been elected to the Board of Directors of Sequenom, Inc. , and will be Chairman of the Audit Committee, it was announced today by Harry Hixson, Jr., Ph.D., Chairman of the Board of Directors. Also, it was announced that John Sharp, currently Sequenom’s Vice President of Finance, has been appointed Sequenom’s Treasurer and designated Principal Financial Officer.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)
Mr. Moreau, 62 and currently retired, brings 35 years of experience in public accounting and finance to Sequenom. Previously, Mr. Moreau was the founder of Moreau and Company, Inc. a financial advisory firm and Moreau Capital Corporation, a National Association of Securities Dealers (NASD) registered investment-banking firm, which assisted early and middle-stage growth companies to raise capital from both private and public financing transactions. Prior to founding his own firm, Mr. Moreau was a Board Member and the licensed Financial Principal of a New York Stock Exchange (NYSE) investment-banking firm. Mr. Moreau also served as Vice President/Special Assistant Finance to the President of Pacific Enterprises (now Sempra Energy), a multi-billion dollar diversified holding company. He began his career with Touche Ross & Co. (now Deloitte & Touche) where he spent 11 years with the firm’s auditing division.
From 2003 to 2005, Mr. Moreau served on the Board of Directors of InterMix Media, a leading Internet content provider. As Chairman of their Audit Committee and a member of their Corporate Governance and Nominating Committee, Moreau played a major role in the Company’s successful financial and corporate governance restructuring and its recent sale to News Corporation. Mr. Moreau also serves on the Board of Chatsworth Products, Inc. a private company in the computer hardware industry.
He holds a Bachelor of Arts in Accounting and Master’s degree in Accounting Science from the University of Illinois. His credentials include: licensed as both a Financial Principal and an Operations Principal with the NASD; an Associate Member of the NYSE; and member of the Securities and Exchange Commission (SEC) practice section of the American Institute of Certified Public Accountants. He is a member of the National Association of Corporate Directors and is a graduate of UCLA’s Corporate Director Certification Program. He currently serves on the planning committee of the SEC’s Small Business Forum.
Mr. Sharp has served as Sequenom’s Vice President, Finance since November 2004. Before joining Sequenom, Mr. Sharp was Director of Accounting at Diversa Corporation, a publicly-traded biotech company, from August 2000 to November 2004, where he was responsible for managing the overall accounting function, including internal controls and corporate governance. During that period, revenues grew from $24 million to almost $60 million and headcount increased from 200 to over 300. From January 1994 to August 2000, Mr. Sharp was a Senior Audit Manager while at the public accounting firm of PricewaterhouseCoopers. Mr. Sharp received a Bachelor of Science degree in Accounting from San Diego State University and is a Certified Public Accountant. Mr. Sharp is also a member of the Association of Bioscience Financial Officers.
“Larry brings an exceptional background in financial planning as well as private and public financing to Sequenom’s board,” said Dr. Hixson. “As the Company progresses on its refined business strategy, Larry’s leadership and oversight, together with John’s financial management expertise will be most beneficial in Sequenom realizing its goals.”
About Sequenom
Sequenom is committed to providing the best genetic analysis products that translate genomic science into superior solutions for biomedical research, molecular medicine and agricultural applications. The Company’s proprietary MassARRAY(R) system is a high-performance DNA analysis platform that efficiently and precisely measures the amount of genetic target material and variations therein. The system is able to deliver reliable and specific data from complex biological samples and from genetic target material that is only available in trace amounts.
Sequenom(R) and MassARRAY(R) are trademarks of Sequenom, Inc.
Except for the historical information contained herein, the matters set forth in this press release, including statements related to Sequenom’s business strategy and the impact members of management and the board of directors may have on Sequenom’s business, financial condition and prospects, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Sequenom’s technologies, the development and commercialization of any new service, technology, product or application, and Sequenom’s ability to execute its business strategy, and other risks detailed from time to time in Sequenom’s SEC filings, including Sequenom’s Annual Report on Form 10-K for the year ended December 31, 2004, and its most recently filed quarterly report on Form 10-Q. These forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comSequenom, Inc.
CONTACT: Investor Relations, Amy Caterina of Sequenom, Inc.,+1-858-202-9033, acaterina@sequenom.com
